Literature DB >> 23166389

Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods.

Susan M Landau1, Christopher Breault, Abhinay D Joshi, Michael Pontecorvo, Chester A Mathis, William J Jagust, Mark A Mintun.   

Abstract

UNLABELLED: (11)C-Pittsburgh compound B ((11)C-PiB) and (18)F-florbetapir amyloid-β (Aβ) PET radioligands have had a substantial impact on Alzheimer disease research. Although there is evidence that both radioligands bind to fibrillar Aβ in the brain, direct comparisons in the same individuals have not been reported. Here, we evaluated PiB and florbetapir in a retrospective convenience sample of cognitively normal older controls, patients with mild cognitive impairment, and patients with Alzheimer disease from the Alzheimer's Disease Neuroimaging Initiative (ADNI).
METHODS: From the ADNI database, 32 participants were identified who had undergone at least 1 PiB study and subsequently underwent a florbetapir study approximately 1.5 y after the last PiB study. Cortical PiB and florbetapir retention was quantified using several different methods to determine the effect of preprocessing factors (such as smoothing and reference region selection) and image processing pipelines.
RESULTS: There was a strong association between PiB and florbetapir cortical retention ratios (Spearman ρ = 0.86-0.95), and these were slightly lower than cortical retention ratios for consecutive PiB scans (Spearman ρ = 0.96-0.98) made approximately 1.1 y apart. Cortical retention ratios for Aβ-positive subjects tended to be higher for PiB than for florbetapir images, yielding slopes for linear regression of florbetapir against PiB of 0.59-0.64. Associations between consecutive PiB scans and between PiB and florbetapir scans remained strong, regardless of processing methods such as smoothing, spatial normalization to a PET template, and use of reference regions. The PiB-florbetapir association was used to interconvert cutoffs for Aβ positivity and negativity between the 2 radioligands, and these cutoffs were highly consistent in their assignment of Aβ status.
CONCLUSION: PiB and florbetapir retention ratios were strongly associated in the same individuals, and this relationship was consistent across several data analysis methods, despite scan-rescan intervals of more than a year. Cutoff thresholds for determining positive or negative Aβ status can be reliably transformed from PiB to florbetapir units or vice versa using a population scanned with both radioligands.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23166389      PMCID: PMC3747730          DOI: 10.2967/jnumed.112.109009

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  18 in total

1.  In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).

Authors:  Dean F Wong; Paul B Rosenberg; Yun Zhou; Anil Kumar; Vanessa Raymont; Hayden T Ravert; Robert F Dannals; Ayon Nandi; James R Brasić; Weiguo Ye; John Hilton; Constantine Lyketsos; Hank F Kung; Abhinay D Joshi; Daniel M Skovronsky; Michael J Pontecorvo
Journal:  J Nucl Med       Date:  2010-06       Impact factor: 10.057

2.  Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects.

Authors:  E C Mormino; J T Kluth; C M Madison; G D Rabinovici; S L Baker; B L Miller; R A Koeppe; C A Mathis; M W Weiner; W J Jagust
Journal:  Brain       Date:  2008-11-28       Impact factor: 13.501

3.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging.

Authors:  Christopher C Rowe; Kathryn A Ellis; Miroslava Rimajova; Pierrick Bourgeat; Kerryn E Pike; Gareth Jones; Jurgen Fripp; Henri Tochon-Danguy; Laurence Morandeau; Graeme O'Keefe; Roger Price; Parnesh Raniga; Peter Robins; Oscar Acosta; Nat Lenzo; Cassandra Szoeke; Olivier Salvado; Richard Head; Ralph Martins; Colin L Masters; David Ames; Victor L Villemagne
Journal:  Neurobiol Aging       Date:  2010-05-15       Impact factor: 4.673

4.  18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

Authors:  Rik Vandenberghe; Koen Van Laere; Adrian Ivanoiu; Eric Salmon; Christine Bastin; Eric Triau; Steen Hasselbalch; Ian Law; Allan Andersen; Alex Korner; Lennart Minthon; Gaëtan Garraux; Natalie Nelissen; Guy Bormans; Chris Buckley; Rikard Owenius; Lennart Thurfjell; Gill Farrar; David J Brooks
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

5.  Use of florbetapir-PET for imaging beta-amyloid pathology.

Authors:  Christopher M Clark; Julie A Schneider; Barry J Bedell; Thomas G Beach; Warren B Bilker; Mark A Mintun; Michael J Pontecorvo; Franz Hefti; Alan P Carpenter; Matthew L Flitter; Michael J Krautkramer; Hank F Kung; R Edward Coleman; P Murali Doraiswamy; Adam S Fleisher; Marwan N Sabbagh; Carl H Sadowsky; Eric P Reiman; P Eric M Reiman; Simone P Zehntner; Daniel M Skovronsky
Journal:  JAMA       Date:  2011-01-19       Impact factor: 56.272

6.  Reducing between scanner differences in multi-center PET studies.

Authors:  Aniket Joshi; Robert A Koeppe; Jeffrey A Fessler
Journal:  Neuroimage       Date:  2009-02-06       Impact factor: 6.556

7.  Relationships between biomarkers in aging and dementia.

Authors:  W J Jagust; S M Landau; L M Shaw; J Q Trojanowski; R A Koeppe; E M Reiman; N L Foster; R C Petersen; M W Weiner; J C Price; C A Mathis
Journal:  Neurology       Date:  2009-10-13       Impact factor: 9.910

8.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.

Authors:  William E Klunk; Henry Engler; Agneta Nordberg; Yanming Wang; Gunnar Blomqvist; Daniel P Holt; Mats Bergström; Irina Savitcheva; Guo-feng Huang; Sergio Estrada; Birgitta Ausén; Manik L Debnath; Julien Barletta; Julie C Price; Johan Sandell; Brian J Lopresti; Anders Wall; Pernilla Koivisto; Gunnar Antoni; Chester A Mathis; Bengt Långström
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

9.  Amyloid deposition, hypometabolism, and longitudinal cognitive decline.

Authors:  Susan M Landau; Mark A Mintun; Abhinay D Joshi; Robert A Koeppe; Ronald C Petersen; Paul S Aisen; Michael W Weiner; William J Jagust
Journal:  Ann Neurol       Date:  2012-10       Impact factor: 10.422

10.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.

Authors:  Milos D Ikonomovic; William E Klunk; Eric E Abrahamson; Chester A Mathis; Julie C Price; Nicholas D Tsopelas; Brian J Lopresti; Scott Ziolko; Wenzhu Bi; William R Paljug; Manik L Debnath; Caroline E Hope; Barbara A Isanski; Ronald L Hamilton; Steven T DeKosky
Journal:  Brain       Date:  2008-03-12       Impact factor: 13.501

View more
  189 in total

1.  Mapping 3-year changes in gray matter and metabolism in Aβ-positive nondemented subjects.

Authors:  Miguel Ángel Araque Caballero; Matthias Brendel; Andreas Delker; Jinyi Ren; Axel Rominger; Peter Bartenstein; Martin Dichgans; Michael W Weiner; Michael Ewers
Journal:  Neurobiol Aging       Date:  2015-08-18       Impact factor: 4.673

2.  The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

Authors:  E Cavedo; S Lista; Z Khachaturian; P Aisen; P Amouyel; K Herholz; C R Jack; R Sperling; J Cummings; K Blennow; S O'Bryant; G B Frisoni; A Khachaturian; M Kivipelto; W Klunk; K Broich; S Andrieu; M Thiebaut de Schotten; J-F Mangin; A A Lammertsma; K Johnson; S Teipel; A Drzezga; A Bokde; O Colliot; H Bakardjian; H Zetterberg; B Dubois; B Vellas; L S Schneider; H Hampel
Journal:  J Prev Alzheimers Dis       Date:  2014-12

Review 3.  Repetitive Head Impacts and Chronic Traumatic Encephalopathy.

Authors:  Ann C McKee; Michael L Alosco; Bertrand R Huber
Journal:  Neurosurg Clin N Am       Date:  2016-10       Impact factor: 2.509

4.  Correlation between two methods of florbetapir PET quantitative analysis.

Authors:  Christopher Breault; Jonathan Piper; Abhinay D Joshi; Sara D Pirozzi; Aaron S Nelson; Ming Lu; Michael J Pontecorvo; Mark A Mintun; Michael D Devous
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-07-15

5.  Amyloid burden accelerates white matter degradation in cognitively normal elderly individuals.

Authors:  Ashwati Vipin; Kwun Kei Ng; Fang Ji; Hee Youn Shim; Joseph K W Lim; Ofer Pasternak; Juan Helen Zhou
Journal:  Hum Brain Mapp       Date:  2019-01-03       Impact factor: 5.038

6.  Aβ-related hyperactivation in frontoparietal control regions in cognitively normal elderly.

Authors:  Hwamee Oh; Jason Steffener; Qolamreza R Razlighi; Christian Habeck; Dan Liu; Yunglin Gazes; Sarah Janicki; Yaakov Stern
Journal:  Neurobiol Aging       Date:  2015-08-24       Impact factor: 4.673

7.  Amyloid-β Positivity Predicts Cognitive Decline but Cognition Predicts Progression to Amyloid-β Positivity.

Authors:  Jeremy A Elman; Matthew S Panizzon; Daniel E Gustavson; Carol E Franz; Mark E Sanderson-Cimino; Michael J Lyons; William S Kremen
Journal:  Biol Psychiatry       Date:  2020-01-07       Impact factor: 13.382

Review 8.  Amyloid Imaging: Poised for Integration into Medical Practice.

Authors:  Keshav Anand; Marwan Sabbagh
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

9.  Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers.

Authors:  Michael J Properzi; Rachel F Buckley; Jasmeer P Chhatwal; Michael C Donohue; Cristina Lois; Elizabeth C Mormino; Keith A Johnson; Reisa A Sperling; Aaron P Schultz
Journal:  Neuroimage       Date:  2018-11-17       Impact factor: 6.556

10.  Associating a negatively charged GdDOTA-derivative to the Pittsburgh compound B for targeting Aβ amyloid aggregates.

Authors:  André F Martins; Alexandre C Oliveira; Jean-François Morfin; Douglas V Laurents; Éva Tóth; Carlos F G C Geraldes
Journal:  J Biol Inorg Chem       Date:  2015-11-27       Impact factor: 3.358

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.